"EMBARK: A Phase 3b, Open-Label, Single-Arm, Safety Study to Evaluate the Long-Term Safety and Efficacy of Aducanumab in Eligible Participants With Alzheimer’s Disease (2448)." Neurology
96.15 Supplement
(2021):
2448.
Web. 29 Nov. 2023.
Advertisement